glp-1 cardiovascular outcomes 2025 news ISPOR 2025: Exploring reasons for discontinuation SGLTi and GLP-1 in HF

GLP-1s account for 23% of first line diabetes therapy in 2025 up from 3% in 2021 Since 2019, the American Diabetes Association (ADA) has revised its Standards of Care each year to expand the role of GLP-1 receptor agonists and SGLT2 inhibitors as first-line treatments for T2D 2

Most hormone clinics in Louisiana cannot make this claim

Contamination by microorganisms can lead to the production of proteases that rapidly digest Retatrutide

Clinical Trial Efficacy Data The approval is backed by two pivotal Phase 3 trials within the CORALreef clinical program evaluated at week 24: CORALreef Lipids Trial: Achieved a statistically significant 56% placebo-adjusted reduction in LDL-C (with a post-hoc analysis showing a 60% reduction when biological inconsistencies were removed)

Chia Pudding: 2 tbsp chia seeds in cup unsweetened almond milk (overnight)10g fiber, 5g protein